There has been much debate about whether there is a global deterioration of IP, and many commentators would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India.
In late 2011, India adopted a National Manufacturing Policy to boost gross domestic product from 16 percent to 25 percent by 2022. The policy aims to aggressively increase domestic manufacturing capacity, especially in high technology areas.
One mechanism to achieve this goal is by adopting measures that “ensure access for Indian companies to foreign technologies” by “leveraging the strength of India’s large market”. The official policy further elaborates that one way to ensure access to foreign technologies requires India to overhaul its IP regime “to enable more collaborative innovation.”
During the 2012 general assemblies of the World Intellectual Property Organization (WIPO), India proclaimed that “while fully recognising the importance of IP rights for innovation—diffusion of technology also merits serious consideration.”
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
India, biopharma, deterioration of IP, biopharma innovation, compulsory licences
